Flamel Technologies Announces Product Partnership Agreement
06 6월 2013 - 10:53PM
Marketwired
Flamel Technologies (NASDAQ: FLML) today announced a multi-year
development partnership agreement with an undisclosed, large
international pharmaceutical company. The development work, which
will be done in Flamel's Bordeaux facility, is expected to generate
revenue of over $4 million over the next several years and has the
potential for expansion.
"The development agreement recognizes Flamel's expertise and
strength in our development and manufacturing capabilities for
difficult- to-manufacture products," said Mike Anderson, Chief
Executive Officer of Flamel. "We are very pleased that the proven
success of product development and manufacturing in our Bordeaux
facility is reinforced with this new product development
partnership."
About Flamel Technologies. Flamel
Technologies SA's (NASDAQ: FLML) business model is to blend
high-value internally developed products with its leading drug
delivery capabilities. The Company has a proprietary pipeline of
niche specialty pharmaceutical products, while its drug delivery
platforms are focused on the goal of developing safer, more
efficacious formulations of drugs to address unmet medical needs.
Its partnered pipeline includes biological and chemical drugs
formulated with its Medusa® and Micropump® (and its applications to
the development of liquid formulations, i.e. LiquiTime™ and of
abuse-deterrent formulations Trigger Lock™) proprietary drug
delivery platforms. Several Medusa-based products have been
successfully tested in clinical trials. The Company has developed
products and manufactures Micropump-based microparticles under
FDA-audited GMP guidelines. Flamel Technologies has collaborations
with a number of leading pharmaceutical and biotechnology
companies, including GlaxoSmithKline (Coreg CR®, carvedilol
phosphate). The Company is headquartered in Lyon, France and has
operations in St. Louis, Missouri, USA, and manufacturing
facilities in Pessac, France. Additional information may be found
at www.flamel.com.
Safe Harbor This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including certain plans,
expectations, goals and projections regarding financial results,
product developments and technology platforms. All statements that
are not clearly historical in nature are forward-looking, and the
words "anticipate," "assume," "believe," "expect," "estimate,"
"plan," "will," "may," and similar expressions are generally
intended to identify forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control that could
cause actual results to differ materially from those contemplated
in such forward-looking statements. These risks include risks that
the continued integration of Éclat Pharmaceuticals may not be
successful or that certain payment acceleration events may be
triggered; the reacquisition of the exclusive rights to develop and
commercialize IFN-β XL worldwide and identification of an
alternative strategic partner for the program may not be
successful; the identified opportunities will not result in
shorter-term, high value results; clinical trial results may not be
positive or our partners may decide not to move forward; products
in the development stage may not achieve scientific objectives or
milestones or meet stringent regulatory requirements; products in
development may not achieve market acceptance; competitive products
and pricing may hinder our commercial opportunities; we may not be
successful in identifying and pursuing opportunities to develop our
own product portfolio using Flamel's technology; and the risks
associated with our reliance on outside parties and key strategic
alliances. These and other risks are described more fully in
Flamel's Annual Report on Form 20-F for the year ended December 31,
2012 that has been filed with the Securities and Exchange
Commission (SEC). All forward-looking statements included in this
release are based on information available at the time of the
release. We undertake no obligation to update or alter our
forward-looking statements as a result of new information, future
events or otherwise.
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024